Cocrystal Pharma
COCP
21 hedge funds and large institutions have $1.47M invested in Cocrystal Pharma in 2023 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 3 increasing their positions, 4 reducing their positions, and 2 closing their positions.
0% more funds holding
Funds holding: 21 → 21 (0)
0% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 2
4.02% less ownership
Funds ownership: 13.1% → 9.08% (-4%)
25% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 4
29% less capital invested
Capital invested by funds: $2.08M → $1.47M (-$610K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$46.3K |
| 2 |
Renaissance Technologies
New York
|
+$12.9K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
+$8.49K |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$9 |
| 5 |
Wells Fargo
San Francisco,
California
|
+$2 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$792K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$6.75K |
| 3 |
Bank of America
Charlotte,
North Carolina
|
-$36 |
| 4 |
PNC Financial Services Group
Pittsburgh,
Pennsylvania
|
-$36 |
| 5 |
NA
NewEdge Advisors
New Orleans,
Louisiana
|
-$35 |
COCP Hedge Fund Activity: Q1 2023 in Review
21 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Cocrystal Pharma (COCP) for Q1 2023, worth a combined $1.47M — down 29% from $2.08M a quarter earlier.
Fund positioning in COCP was balanced in Q1 2023: 2 funds opened new positions, 2 closed out, 3 added to existing stakes and 4 trimmed.
The largest buyer was Susquehanna International Group, opening a new position worth an estimated $46.3K. The largest seller was Sabby Management, cutting an estimated $792K.
- 21 institutional investors held Cocrystal Pharma (COCP) as of Q1 2023, unchanged from Q4 2022.
- Funds reported $1.47M of Cocrystal Pharma stock for Q1 2023, down 29% quarter-over-quarter.
- 2 funds opened new Cocrystal Pharma positions in Q1 2023 and 2 closed out, a net change of 0 holders.
- The largest Cocrystal Pharma buyer in Q1 2023 was Susquehanna International Group, an estimated $46.3K added.
- The largest Cocrystal Pharma seller in Q1 2023 was Sabby Management, an estimated $792K sold.
Based on aggregated 13F filings for Q1 2023.